Literature DB >> 20961300

Gut lymph and lymphatics: a source of factors leading to organ injury and dysfunction.

Edwin A Deitch1.   

Abstract

Major trauma, shock, sepsis, and other conditions can lead to the acute respiratory distress syndrome (ARDS), which may progress to the highly lethal multiple organ dysfunction syndrome (MODS). Although a number of therapeutic strategies have been initiated, their success has been limited largely due to an incomplete understanding of the biology of MODS. However, recent studies indicate that the intestinal lymphatics serve as the primary route for nonbacterial, tissue injurious gut-derived factors, which can induce acute ARDS and MODS. The gut lymph hypothesis of ARDS and MODS thus helps clarify several important issues. First, because the lung is the first organ exposed to mesenteric lymph and not the liver (i.e., mesenteric lymph enters the subclavian vein via the thoracic duct, which, in turn, empties directly into the heart and lungs), it would explain the clinical observation that the lung is generally the first organ to fail. Second, this hypothesis provides new pathophysiologic information, thereby providing a basis for novel therapies. Finally, by studying the composition of lymph, MODS-inducing factors can be isolated and identified.
© 2010 New York Academy of Sciences.

Entities:  

Mesh:

Year:  2010        PMID: 20961300     DOI: 10.1111/j.1749-6632.2010.05713.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  73 in total

1.  Enterocytes' tight junctions: From molecules to diseases.

Authors:  Stelios F Assimakopoulos; Ismini Papageorgiou; Aristidis Charonis
Journal:  World J Gastrointest Pathophysiol       Date:  2011-12-15

Review 2.  Strategies to Modulate MicroRNA Functions for the Treatment of Cancer or Organ Injury.

Authors:  Tae Jin Lee; Xiaoyi Yuan; Keith Kerr; Ji Young Yoo; Dong H Kim; Balveen Kaur; Holger K Eltzschig
Journal:  Pharmacol Rev       Date:  2020-07       Impact factor: 25.468

Review 3.  Perioperative organ injury.

Authors:  Karsten Bartels; Jörn Karhausen; Eric T Clambey; Almut Grenz; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2013-12       Impact factor: 7.892

Review 4.  From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity.

Authors:  Natalie L Trevaskis; Lisa M Kaminskas; Christopher J H Porter
Journal:  Nat Rev Drug Discov       Date:  2015-10-16       Impact factor: 84.694

5.  Post-shock mesenteric lymph drainage ameliorates cellular immune function in rats following hemorrhagic shock.

Authors:  Hua Liu; Zi-Gang Zhao; Li-Qiang Xing; Li-Min Zhang; Chun-Yu Niu
Journal:  Inflammation       Date:  2015-04       Impact factor: 4.092

Review 6.  Lymphatic transport of high-density lipoproteins and chylomicrons.

Authors:  Gwendalyn J Randolph; Norman E Miller
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 7.  Targeting Hypoxia Signaling for Perioperative Organ Injury.

Authors:  Xiaoyi Yuan; Jae W Lee; Jessica L Bowser; Viola Neudecker; Srikanth Sridhar; Holger K Eltzschig
Journal:  Anesth Analg       Date:  2018-01       Impact factor: 5.108

8.  Impact of intestinal ischemia/reperfusion and lymph drainage on distant organs in rats.

Authors:  Gui-Zhen He; Kai-Guo Zhou; Rui Zhang; Yu-Kang Wang; Xue-Feng Chen
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

9.  Dual roles of commensal bacteria after intestinal ischemia and reperfusion.

Authors:  Hong-Yi Zhang; Fang Wang; Xuyong Chen; Xinrao Meng; Chenzhao Feng; Jie-Xiong Feng
Journal:  Pediatr Surg Int       Date:  2019-09-20       Impact factor: 1.827

10.  Intestinal mast cells mediate gut injury and systemic inflammation in a rat model of deep hypothermic circulatory arrest.

Authors:  Jörn Karhausen; Ma Qing; Amelia Gibson; Adam J Moeser; Harald Griefingholt; Laura P Hale; Soman N Abraham; G Burkhard Mackensen
Journal:  Crit Care Med       Date:  2013-09       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.